{"id":348,"date":"2020-07-07T05:58:24","date_gmt":"2020-07-07T05:58:24","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=348"},"modified":"2020-07-07T05:58:24","modified_gmt":"2020-07-07T05:58:24","slug":"05-july-2020-lopinavir-ritonavir-associated-with-faster-pneumonia-resolution-within-two-weeks-after-symptom-onset-37-vs-1-p0-001","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/05-july-2020-lopinavir-ritonavir-associated-with-faster-pneumonia-resolution-within-two-weeks-after-symptom-onset-37-vs-1-p0-001\/","title":{"rendered":"(05 July 2020) Lopinavir\/Ritonavir- associated with faster pneumonia resolution within two weeks after symptom onset (37% vs 1%, P=0.001)"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Lopinavir\/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study<\/p>\n<p class=\"\"><a href=\"https:\/\/doi.org\/10.1002\/jmv.26260\">https:\/\/doi.org\/10.1002\/jmv.26260<\/a><\/p>\n<p class=\"\">This is a retrospective study of 128 hospitalized patients with COVID-19 pneumonia. All patients were positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive by nucleic acid detection. 64 cases were co-infected with influenza A\/B and the other 64 were influenza negative, matched by age, sex, and days from onset of symptoms. Among the 64 co-infected patients, 54 (84.4%) were co-infected with influenza A, and 10 (15.6%) with influenza B. The median duration of viral shedding time from admission was longer for patients with influenza coinfection (17.0 days) than for those without influenza coinfection (12.0 days) (P&lt;0.001). The multivariable Cox proportional hazards model showed that the hazard ratio HR of resolution in lung involvement was 1.878 (P=0.020) for patients administered lopinavir\/ritonavir, compared with those not administered lopinavir\/ritonavir (95% confidence interval (CI) 1.103, 3.196). Among influenza co-infected patients, those treated with lopinavir\/ritonavir exhibited faster pneumonia resolution within two weeks after symptom onset (37% vs 1%, P=0.001). There was no difference in lung involvement between influenza co-infected and non-infected groups. Lopinavir\/ritonavir eliminated the difference of lung involvement between influenza co-infected and non-infected groups, indicating that lopinavir\/ritonavir is associated with pneumonia resolution in COVID-19.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lopinavir\/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study https:\/\/doi.org\/10.1002\/jmv.26260 This is a retrospective study of 128 hospitalized patients with COVID-19 pneumonia. All patients were positive severe acute respiratory syndrome coronavirus 2&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/05-july-2020-lopinavir-ritonavir-associated-with-faster-pneumonia-resolution-within-two-weeks-after-symptom-onset-37-vs-1-p0-001\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(05 July 2020) Lopinavir\/Ritonavir- associated with faster pneumonia resolution within two weeks after symptom onset (37% vs 1%, P=0.001)&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,12],"tags":[41],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/348"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=348"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/348\/revisions"}],"predecessor-version":[{"id":349,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/348\/revisions\/349"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}